CorMedix Inc. (CRMD) Form 8-K — May 14, 2026

$CRMDForm 8-KItems 2.02, 9.01Filed May 14, 2026, 7:34 AM ET0001410098-26-000020Original filing

CorMedix Inc. reported strong financial results for the first quarter of 2026, with net revenue of $127.4 million, a significant increase from $39.1 million in the same period of 2025. The company also recognized net income of $38.6 million, or $0.48 per basic share, compared to $20.6 million, or $0.32 per basic share, in the first quarter of 2025. DefenCath® sales contributed $97.5 million to the net revenue, bolstered by higher utilization and a non-recurring $9.0 million favorable change in estimate related to certain sales allowances.

Key figures

Eps: 0.48
Revenue: 127427
Guidance: FY 2026 net revenue guidance: $325 to $345 million; FY 2026 adjusted EBITDA guidance: $115 to $135 million
Net Income: 38601
Total Debt: 378588
Total Assets: 815637
Cash Position: 178087

Price after filing

1 day: 0.0%7 days: +1.6%30 days: +13.0%

Close on the filing date to close N calendar days later (from $7.93). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.